Sort   by:  
 Page size 
GenomicsTFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma
TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma
PRJNA1160153 | ENA
GenomicsDifferential mRNA expression analysis of EGFR-TKI-sensitive cells vs. EGFR-TKI-resistant cells
Differential mRNA expression analysis of EGFR-TKI-sensitive cells vs. EGFR-TKI-resistant cells
PRJNA721680 | ENA
ProteomicsTKI-resistant T790M EGFR Mutation Rewired EGFR Translocation Routes through Switching Interactome in Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) harboring active mutations, Del19 and L858R, are most common oncogenic mutations in in non-small cell lung cancer (NSCLC) patients. The preferred treatment at first line is tyrosine kinase inhibitor (TKI) administration while the TKI-resistance usually develop...
ORGANISM(S): Homo Sapiens (human) 
2023-05-31 | PXD034228 | JPOST Repository
TranscriptomicsMicroarray expression profile of long noncoding RNAs in EGFR-TKI resistance of lung adenocarcinoma
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Prolonged cancer treatment will induce the development of acquired resistance to EGFR TKI. To gain insight into the molecular mechanisms of EGFR-TKIs resista...
ORGANISM(S): Homo sapiens 
2016-08-23 | E-GEOD-74575 | biostudies-arrayexpress
GenomicsWhole exome sequencing of EGFR-TKI naive and EGFR-TKI resistant lung adenocarcinoma samples
Whole exome sequencing of EGFR-TKI naive and EGFR-TKI resistant lung adenocarcinoma samples
PRJEB50602 | ENA
GenomicsTranscriptome profiling to determine molecular mechanisms of acquired EGFR TKI resistance
Transcriptome profiling to determine molecular mechanisms of acquired EGFR TKI resistance
PRJNA497901 | ENA
ProteomicsGlobal proteome and phosphoproteome alterations in 3rd generation EGFR TKI resistance reveal drug targets to circumvent resistance
Lung cancer continues to be the leading cause of cancer mortality worldwide. The treatment of lung cancer patients harboring mutant EGFR with orally administered EGFR TKIs has been a paradigm shift. Osimertinib and rociletinib are two 3rd generation irreversible EGFR TKIs targeting the EGFR T790M mu...
ORGANISM(S): Homo sapiens (Human) 
2021-03-11 | PXD020108 | Pride
Resistance mechanism Lung adenocarcinoma 3rd generation egfr tki 
ProteomicsResearch on the mechanism by which cancer-associated fibroblasts (CAFs) promote EGFR-TKI resistance in non-small cell lung cancer (NSCLC) via secretory proteins
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major clinical challenge in the targeted therapy of non-small cell lung cancer (NSCLC), yet its underlying mechanisms are poorly understood. The tumor microenvironment (TME), which provides a supportive n...
ORGANISM(S): Homo Sapiens 
2025-05-26 | PXD064318 |
TranscriptomicsTFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma
Intrinsic and acquired resistance represent major obstacles to optimize outcomes in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in lung adenocarcinoma (LUAD). Hence, a deeper understanding of EGFR-TKI resistance mechanisms in LUAD will potentially assist ...
ORGANISM(S): Homo sapiens 
2025-10-31 | GSE276990 | GEO
GenomicsWhole exome sequencing of EGFR-TKI naive and EGFR-TKI resistant lung adenocarcinoma samples
Whole exome sequencing was performed on set of 48 DNA samples obtained from 16 EGFR mutated NSCLC patients whose tumors progressed following EGFR-TKI treatment. The DNA samples included baseline biopsy, rebiopsy and blood from the same patient. By comparing the variants in rebiopsy tumors and baseli...
ORGANISM(S): Homo sapiens 
2022-02-11 | E-MTAB-11404 | biostudies-arrayexpress
Sort   by:  
 Page size